JP2011516544A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011516544A5 JP2011516544A5 JP2011503905A JP2011503905A JP2011516544A5 JP 2011516544 A5 JP2011516544 A5 JP 2011516544A5 JP 2011503905 A JP2011503905 A JP 2011503905A JP 2011503905 A JP2011503905 A JP 2011503905A JP 2011516544 A5 JP2011516544 A5 JP 2011516544A5
- Authority
- JP
- Japan
- Prior art keywords
- mitiglinide
- metformin
- test
- glufast
- tablets
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960003365 mitiglinide Drugs 0.000 claims description 12
- WPGGHFDDFPHPOB-BBWFWOEESA-N mitiglinide Chemical compound C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)O)C1=CC=CC=C1 WPGGHFDDFPHPOB-BBWFWOEESA-N 0.000 claims description 11
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 7
- 229960003105 metformin Drugs 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000007884 disintegrant Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000314 lubricant Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- QEVLNUAVAONTEW-UZYHXJQGSA-L calcium;(2s)-4-[(3as,7ar)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]-2-benzyl-4-oxobutanoate;dihydrate Chemical compound O.O.[Ca+2].C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)[O-])C1=CC=CC=C1.C([C@@H](CC(=O)N1C[C@@H]2CCCC[C@@H]2C1)C(=O)[O-])C1=CC=CC=C1 QEVLNUAVAONTEW-UZYHXJQGSA-L 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 3
- 238000007922 dissolution test Methods 0.000 description 3
- 229940095884 glucophage Drugs 0.000 description 3
- 238000010828 elution Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- JQMFQLVAJGZSQS-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-N-(2-oxo-3H-1,3-benzoxazol-6-yl)acetamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)NC1=CC2=C(NC(O2)=O)C=C1 JQMFQLVAJGZSQS-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
- WTFUTSCZYYCBAY-SXBRIOAWSA-N 6-[(E)-C-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-N-hydroxycarbonimidoyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C/C(=N/O)/C1=CC2=C(NC(O2)=O)C=C1 WTFUTSCZYYCBAY-SXBRIOAWSA-N 0.000 description 1
- DFGKGUXTPFWHIX-UHFFFAOYSA-N 6-[2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]acetyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)C1=CC2=C(NC(O2)=O)C=C1 DFGKGUXTPFWHIX-UHFFFAOYSA-N 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 235000011116 calcium hydroxide Nutrition 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960004329 metformin hydrochloride Drugs 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2008-0032673 | 2008-04-08 | ||
| KR1020080032673A KR101512386B1 (ko) | 2008-04-08 | 2008-04-08 | 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법 |
| PCT/KR2009/001809 WO2009125975A2 (ko) | 2008-04-08 | 2009-04-08 | 미티글리나이드 및 메트포르민 복합제제 및 그의 제조방법 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011516544A JP2011516544A (ja) | 2011-05-26 |
| JP2011516544A5 true JP2011516544A5 (enExample) | 2013-08-01 |
Family
ID=41162388
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011503905A Pending JP2011516544A (ja) | 2008-04-08 | 2009-04-08 | ミチグリニドおよびメトホルミンの複合製剤並びにその製造方法 |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP2011516544A (enExample) |
| KR (1) | KR101512386B1 (enExample) |
| CN (1) | CN101990427A (enExample) |
| TW (1) | TW200946111A (enExample) |
| WO (1) | WO2009125975A2 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
| BR112012011726A2 (pt) * | 2009-11-13 | 2020-05-19 | Bristol-Myers Squibb Company | comprimidos de duas camadas, seu uso, e suas combinações farmacêuticas |
| JP6227406B2 (ja) | 2010-05-11 | 2017-11-08 | ヤンセン ファーマシューティカ エヌ．ベー． | ＳＧＬＴの阻害剤としての１−（β−Ｄ−グルコピラノシル）−２−チエニル−メチルベンゼン誘導体を含有する医薬製剤 |
| WO2012006298A2 (en) * | 2010-07-06 | 2012-01-12 | Janssen Pharmaceutica Nv | Formulation for co-therapy treatment of diabetes |
| KR101441355B1 (ko) * | 2013-05-29 | 2014-09-17 | 주식회사 다림바이오텍 | 레파글리니드 및 메트포르민을 함유하는 이층정 및 그의 제조방법 |
| JP7680822B2 (ja) * | 2017-08-08 | 2025-05-21 | 日本ケミファ株式会社 | 糖尿病治療剤 |
| CN110840855B (zh) * | 2019-11-27 | 2022-04-12 | 哈尔滨珍宝制药有限公司 | 依托考昔片及其制备方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA03003870A (es) * | 2000-10-30 | 2004-08-12 | Johnson & Johnson | Terapia de combinacion que comprende agentes antidiabeticos y anticonvulsionantes. |
| KR100705210B1 (ko) * | 2004-09-23 | 2007-04-06 | 주식회사 한독약품 | 경구투여를 위한 당뇨병 치료용 약제학적 복합제제 |
| KR100760430B1 (ko) * | 2004-12-31 | 2007-10-04 | 한미약품 주식회사 | 당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법 |
| MXPA05010977A (es) * | 2005-10-12 | 2007-04-11 | Abdala Leopoldo Espinosa | Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus. |
| US20070172525A1 (en) * | 2007-03-15 | 2007-07-26 | Ramesh Sesha | Anti-diabetic combinations |
-
2008
- 2008-04-08 KR KR1020080032673A patent/KR101512386B1/ko not_active Expired - Fee Related
-
2009
- 2009-04-08 WO PCT/KR2009/001809 patent/WO2009125975A2/ko not_active Ceased
- 2009-04-08 CN CN2009801124437A patent/CN101990427A/zh active Pending
- 2009-04-08 JP JP2011503905A patent/JP2011516544A/ja active Pending
- 2009-04-08 TW TW098111635A patent/TW200946111A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005512995A5 (enExample) | ||
| JP2011516544A5 (enExample) | ||
| JP2009545560A5 (enExample) | ||
| JP2009525343A5 (enExample) | ||
| JP2008535867A5 (enExample) | ||
| EA200700049A1 (ru) | Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением | |
| JP2005508331A5 (enExample) | ||
| CA2601289A1 (en) | Once-a-day oxycodone formulations | |
| HRP20221269T1 (hr) | Pripravci za liječenje mijelofibroze | |
| RU2005115855A (ru) | Композиция трамадола продлонгированного высвобождением с 24-часовым действием | |
| JP2008543936A5 (enExample) | ||
| CA2858522A1 (en) | Methods for treating cardiovascular disorder | |
| RU2009142937A (ru) | Тапентадол для лечения в связи с остеоартрозом | |
| JP2005528430A5 (enExample) | ||
| JP2006514100A5 (enExample) | ||
| JP2012533559A5 (enExample) | ||
| JP2019529570A5 (enExample) | ||
| WO2003005967A2 (en) | Dual release levodopa ethyl ester and decarboxylase in controlled release core | |
| MX2010007281A (es) | Composiciones farmaceuticas de amlodipina y valsartan. | |
| JP5208729B2 (ja) | 徐放性錠剤の製造方法 | |
| IL174830A0 (en) | Pellets containing venlafaxine hydrochloride, pharmaceutical compositions comprising them and processes for their preparation | |
| JP2018039810A5 (enExample) | ||
| US20060159751A1 (en) | Controlled release pharmaceutical compositions of carbidopa and levodopa | |
| CA2825690A1 (en) | Pharmaceutical formulation | |
| JP2004522780A5 (enExample) |